Comparison To Peers: Boston Scientific Corporation (BSX), McKesson Corporation (MCK)

Boston Scientific Corporation (NYSE:BSX) shares were trading higher by 0.32 percent ($0.09) at $28.45 a piece in Monday’s session. It had closed the previous session at $28.36. BSX trades with a P/S ratio of 4.46. This is higher than the industry’s 3.03 but lower compared with the wider sector’s 5.08. A low price-to-sales ratio, typically less than 1.0, is considered a good value. Also, it has an estimated price-earnings (P/E) multiple of 20.26 and a trailing 12-month price-earnings (P/E) multiple of 46.95. Shares of BSX have uptrended 7.48% in the past three months, while the S&P 500 has moved 1.52% in that time. Boston Scientific Corporation (BSX) has a market cap of $39.38 billion and over the last 12 months, Boston Scientific Corporation (NYSE:BSX) has gone stronger by 32.33%. During the last 52 weeks, the (NYSE:BSX) price has been as high as $29.93 and as low as $19.67. Boston Scientific Corporation earnings have declined with an annualized rate of -2.8% over the last 5 years.

Boston Scientific Corporation (Mean Target Price: $31.67)

The average 1-year price target for Boston Scientific Corporation (BSX) — averaging the work of different analysts — reveals a mean PT of $31.67/share. That’s a potential 11.32 increase relative to where Boston Scientific Corporation (NYSE:BSX) has been trading recently. The current price is seen ranging between $28.19 and $28.61. There are brokerage firms with lower targets than the average, including one setting a price target of $24. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $.

Boston Scientific Corporation (BSX) Consensus Recommendation

The collective rating of 1.8 for Boston Scientific Corporation (NYSE:BSX) also leans strongly towards the bullish end of the spectrum. Of the 24 analysts surveyed by Reuters that track BSX 6 of them rate its stock a hold. The other 18, though not evenly; between analysts who think you should buy Boston Scientific Corporation versus those who think you should sell it. A 18 analysts rate it as either a buy or a strong buy, while0 believe that investors should either steer clear of BSX or, if they already own its stock, sell it.

Is McKesson Corporation (NYSE:MCK) Cheap From Peers?

McKesson Corporation (MCK) pulled off a 0.32 percent gain and now trades for $138.05. MCK comes in with a P/S ratio of 0.15 that’s below 1, potentially implying that it could be cheap relative to the overall sector (6.05) and its peers (1.66). Also, it has an estimated price-earnings (P/E) multiple of 10.65 and a trailing 12-month price-earnings (P/E) multiple of 6.54. During the last 52 weeks, the price has been as high as $169.29 and as low as $133.82. McKesson Corporation (NYSE:MCK) earnings have risen with a quarterly rate of 10.2% over the last 5 years. Shares of MCK have sank -7.51% in the past three monthswhile the S&P 500 has dropped -13.26% in that time.

McKesson Corporation (Price Objective: $173.17)

McKesson Corporation (NYSE:MCK) has a market cap of $29.3 billion and over the last 12 months, MCK has declined by -3.48%. The average 1-year price target for (MCK) reveals an average price target of $173.17 per share. That’s a potential 25.44 gain from where (NYSE:MCK) has been trading recently. There are brokerage firms with lower targets than the average, including one setting a price target of $130. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $210.

Analyst Thoughts About McKesson Corporation (NYSE:MCK)

The consensus recommendation — averaging the work of 14 analysts — of 2.7 for McKesson Corporation (MCK) points to moderate case. Of the analysts surveyed by Reuters that track McKesson Corporation 9 of them rate its stock a hold. The other 5 are split, though not evenly, between analysts who think you should buy its stock versus those who think you should sell it. A 4 analysts rate it as either a buy or a strong buy, while 1 believe that investors should either steer clear of (NYSE:MCK) or, if they already own its stock, sell it.